Future studies will move towards a better understanding of the biology and dynamics of plasma Aβ and Tau in health and disease, as well as vigorous assessment of the clinical utility of IMR-assayed plasma Aβ and Tau in identifying preclinical AD, MCI, and early AD, and the study findings should be comparable with those from CSF biomarker and imaging studies. Here, MAPT is linked to Alzheimer disease.